Abstract
IL13PE38QQR is a recombinant toxin composed of the enzymatically-active portion of Pseudomonas Exotoxin A conjugated with human IL13. Binding of IL13-PE38 to the IL13 receptor (IL13R) permits internalization of the recombinant toxin resulting in selective and potent cytoxicity at nanomolar concentrations. Normal brain tissue expresses little or no IL13R, but malignant gliomas overexpress IL13R conferring the selective cytotoxicity to the agent. Convection-enhanced delivery (CED), a novel direct drug delivery method to tumor and peritumoral region uses positive pressure infusion to generate a pressure gradient that optimizes distribution of macromolecules within the brain. Three phase I studies have been initiated to investigate IL13-PE38QQR as an anti-tumor agent for the treatment of patients with recurrent malignant gliomas. As of January 2003 a total of 46 patients have been treated. The presentation at the March 2003 EANS Local Therapy of Glioma meeting reflects adverse event findings through January 2003 and survival data through March 2003. Intratumoral infusion with or without resection is fairly well-tolerated with corticosteroids prophylaxis particularly for patients with raised intracranial pressure. Post-resection infusion into the peritumoral brain parenchyma also appears to be very well tolerated. Histopathological tumor effect was seen at drug concentrations of 0.5-2.0 µg/mL. Although phase I studies do not focus on efficacy evaluation, prolonged survival times have been observed in this select population of patients. The pre-clinical data and details and preliminary results of the three clinical trials are reviewed.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Bobo R, Laske D, Akbasak A et al (1994) Convection-enhanced delivery of macromolecules in the brain. Proc Nat J Acad Sci 91: 2076–2080
Bochner B, Klunk D, Sterbinski S et al (1995) IL-13 selectively induces vascular cell adhesion molecule-1 expression in human endothelial cells. J Immunol 154: 799–803
Brem H, Piantadosi S, Burger P et al (1995) Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. Lancet 345: 1008–1012
Chen M, Lonser R, Morrison P et al (1999) Variables affecting convection-enhanced delivery to the striatum: a systematic examination of rate of infusion, cannula size, infusate concentration, and tissue-cannula sealing time. J Neurosurg 90: 315–320
Debinski W, Obiri N, Pastan I et al (1995) A novel chimeric protein composed of interleukin 13 and pseudomonas exotoxin is highly cytotoxic to human carcinoma cells expressing receptors for interleukin 13 and interleukin 4. J Biol Chem 270: 16775–16780
Debinski W, Obiri N, Powers S et al (1995) Human glioma cells overexpress receptors for interleukin 13 and are extremely sensitive to a novel chimeric protein composed of interleukin 13 and pseudomonas exotoxin. Clin Cancer Res 1: 1253–1258
Debinski W, Miner R, Leland P et al (1996) Receptor for interleukin 13 does not interact with IL4 but receptor for IL4 interacts with IL13 on human glioma cells. J Biol Chem 271: 22428–22433
Debinski W, Gibo D, Hulet S et al (1999) Receptor for interleukin 13 is a marker and therapeutic target for human high grade gliomas. Clin Cancer Res 5: 985–990
Debinski W, Gibo D, Slagle B et al (1999) Receptor for interleukin 13 is abundantly and specifically over-expressed in patients with glioblastoma multiforme. Int J Oncol 15: 481–486
Defrance T, Carayon P, Billian G et al (1994) Interleukin 13 is a B cell stimulating factor. J Exp Med 179: 135–143
Derocq J, Segui M, Poinot-Chazel C et al (1994) Interleukin-13 stimulates interleukin-6 production by human keratinocytes. Similarity with interleukin-4. FEBS Lett 343: 32–36
Goebeler M, Schnarr B, Toksoy A et al (1997) Interleukin-13 selectively induces monocyte chemoattractant protein-1 synthesis and secretion by human endothelial cells. Involvement of IL-4R alpha and Stat6 phosphorylation. Immunology 91: 450–457
Husain S, Joshi B, Puri RK (2001) Interleukin-13 receptor as a unique target for anti-glioblastoma therapy. Int J Cancer 92: 168–175
Kawakami M, Kawakami K, Puri R (2002) Intratumor administration of interleukin 13 receptor-targeted cytotoxin induces apoptotic cell death in human malignant glioma tumor xenografts. Mol Cancer Ther 1: 999–1007
Kreitman R, Pastan I (1998) Accumulation of a recombinant immunotoxin in a tumor in vivo: fewer than 1000 molecules per cell are sufficient for complete responses. Cancer Res 58: 968–975
Kunwar S, Pai L, Pastan I (1993) Cytotoxicity and antitumor effects of growth factor-toxin fusion proteins on human glioblastoma multiforme cells. J Neurosurg 79: 569–576
Kunwar S, Prados M, Lang F (2003) Intratumoral and peritumoral convection enhanced delivery (CED) of IL13–PE38QQR, a recombinant tumor-targeted cytotoxin, in recurrent malignant glioma-phase I trial. J Neurosurg 98 (Abstract accepted for presentation at American Association Neurological Surgeons Meeting)
Laske D, Youle R, Oldfield E (1997) Tumor regression with regional distribution of the targeted toxin TF-CRM 107 in patients with malignant brain tumors. Nat Med 12: 1362–1368
Lieberman D, Laske D, Morrison P et al (1995) Convection-enhanced distribution of large molecules in gray matter during interstitial drug infusion. J Neurosurg 82: 1021–1029
Morrison P, Laske D, Bob H et al (1994) High-flow micro-infusion: tissue penetration and pharmacodynamics. Am J Physiol 266: R292–R305
Murata T, Obiri N, Debinski W et al (1997) Structure of IL-13 receptor: analysis of subunit composition in cancer and immune cells. Biochem Biophys Res Commun 238: 90–94
Murata T, Taguchi J, Puri R (1998) Interleukin-13 receptor alpha’ but not alpha chain: a functional component of interleukin-4 receptors. Blood 91: 3884–3891
Pastan I, FitzGerald D (1991) Recombinant toxins for cancer treatment. Science 254: 1173
Prabhu S, Broaddus W, Gillies G et al (1998) Distribution of macromolecular dyes in brain using positive pressure infusion: a model for direct controlled delivery of therapeutic agents. Surg Neurol 50: 367–375
Puri R, Hoon D, Leland P et al (1996) Preclinical development of a recombinant toxin containing circularly permuted interleukin 4 and truncated Pseudomonas exotoxin for therapy of malignant astrocytoma. Cancer Res 24: 5631–5637
Schnyder B, Lugli S, Feng N et al (1996) Interleukin-4 (IL-4) and IL-13 bind to a shared heterodimeric complex on endothelial cells mediating vascular cell adhesion molecule-1 induction in the absence of the common gamma chain. Blood 87: 4286–4295
Sironi M, Sciacca F, Matteucci C et al (1994) Regulation of endothelial and mesothelial cell function by interleukin-13: selective induction of vascular cell adhesion molecule-1 and amplification of interleukin-6 production. Blood 84: 1913–1921
Weingart J, Strauss L, Grossman S et al (2002) Phase III study: intra-tumoral infusion of IL13–PE38QQR cytotoxin for recurrent supratentorial malignant glioma. Newoond 4(4): 379
Yung W, Prados M, Yaya-Tur R et al (1999) Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol 17(9): 2762–2771
Yung W, Albright R, Olson J et al (2000) A phase II study of temozolomide vs procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 83(5): 588–593
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Springer-Verlag/Wien
About this paper
Cite this paper
Kunwar, S. (2003). Convection enhanced delivery of IL13-PE38QQR for treatment of recurrent malignant glioma: presentation of interim findings from ongoing phase 1 studies. In: Westphal, M., Tonn, JC., Ram, Z. (eds) Local Therapies for Glioma Present Status and Future Developments. Acta Neurochirurgica Supplements, vol 88. Springer, Vienna. https://doi.org/10.1007/978-3-7091-6090-9_16
Download citation
DOI: https://doi.org/10.1007/978-3-7091-6090-9_16
Publisher Name: Springer, Vienna
Print ISBN: 978-3-211-40355-6
Online ISBN: 978-3-7091-6090-9
eBook Packages: Springer Book Archive